| abstract |
An isolated human anti-TNFα antibody for use in the treatment of moderate to severe rheumatoid arthritis in a human subject, where the antibody has to be administered subcutaneously to the human subject according to a biweekly dosing regimen of 40 mg every 14 days, where The antibody has a light chain variable region (LCVR) comprising the amino acid sequence of the SEC. ID. No. 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of the SEC. ID. No. 2, has a heavy chain constant region of IgG1 and has a constant region of kappa light chain, and where the antibody has to be administered in combination with methotrexate. |